Eloxx Pharmaceuticals, Inc. (ELOX)

Price, with every insider trade on it

Closing prices, 12 months · point at a dot for who traded, or at the line for the close

13.74 on 9 Oct 2026

0 buys0 sales at will0 planned sales

Fiscal year 2025, ended 31 Dec 2025, as filed

Revenue

$0.00

Net income

$6.00M

Free cash flow

$6.33M

Fiscal years, as filed with the SEC · point at a year for the detail

RevenueNet incomeLoss

From Form 4, most recent first

Date	Insider	Type	Value	Of own stake
29 Nov 2021	Geffken Daniel E. INTERIM CFO	Bought	$36.00K	opened
13 May 2021	Nussbaum Ran Director	Bought	$8.00M	opened
13 May 2021	Pontifax Management 4 G.P. (2015) Ltd. 10% owner	Bought	$8.00M	opened
13 May 2021	Kariv Tomer Director	Bought	$8.00M	opened
13 May 2021	PAREKH RAJESH B Director	Bought	$3.33M	104%
24 Jun 2019	Nussbaum Ran Director	Bought	$1.80M	23.5%

20out of 100

Profitability 0

Financial strength 38

Growth 0

Insiders 50

Strongest on insiders (50), weakest on growth (0). A score of the business, not of the price.

Last 12 months

Only here

Bought

$0.00

0 buys, 0 buyers

Sold

$0.00

0 sales

Planned sales

n/a

under a 10b5-1 plan